Asymptomatic peripheral artery disease and antiplatelet management;Thrombozytenaggregationstherapie bei der asymptomatischen peripheren Verschlusskrankheit

Vasa - European Journal of Vascular Medicine

Volumn 43, Issue 5, 2014, Pages 309-325

  Raparelli, Valeria ^a   Proietti, Marco ^a   Napoleone, Laura ^a   Bucci, Tommaso ^a   Talerico, Giovanni ^a   Pignataro, Francesca Serena ^a   Basili, Stefania ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Ankle brachial index; Antiplatelet drugs; Asymptomatic peripheral artery disease; Cardiovascular events; Cardiovascular prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CD40 LIGAND; CLOPIDOGREL; DIPYRIDAMOLE; PADGEM PROTEIN; PICOTAMIDE; PRASUGREL; THIENOPYRIDINE DERIVATIVE; TICAGRELOR;

ANKLE BRACHIAL INDEX; ASYMPTOMATIC DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE COURSE; DRUG EFFICACY; FOLLOW UP; FRAMINGHAM RISK SCORE; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; INTERMITTENT CLAUDICATION; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); PATIENT RISK; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVASCULARIZATION; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SCORING SYSTEM; SCREENING TEST; SYSTEMATIC REVIEW; THROMBOCYTE ACTIVATION; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK;

ANKLE BRACHIAL INDEX; ANTIPLATELET DRUGS; ASYMPTOMATIC PERIPHERAL ARTERY DISEASE; CARDIOVASCULAR EVENTS; CARDIOVASCULAR PREVENTION;

ANKLE BRACHIAL INDEX; ASYMPTOMATIC DISEASES; DISEASE PROGRESSION; EARLY DIAGNOSIS; HUMANS; PERIPHERAL ARTERIAL DISEASE; PLATELET AGGREGATION INHIBITORS; PREDICTIVE VALUE OF TESTS; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84907318158     PISSN: 03011526     EISSN: 16642872     Source Type: Journal    
DOI: 10.1024/0301-1526/a000369     Document Type: Review

References (61)

1. Creager MA, White CJ, Hiatt WR, Criqui MH, Josephs SC, Alberts MJ, Pearce WH, Gray BH, Rocha-Singh KJ; American Heart Association. Atherosclerotic Peripheral Vascular Disease Symposium II: executive summary. Circulation 2008; 118: 2811-2825.
2. Hiatt WR, Goldstone J, SmiThSC Jr, McDermott M, Moneta G, Oka R, Newman AB, Pearce WH; American Heart Association Writing Group 1. Atherosclerotic Peripher al Vascular Disease Symposium II: nomenclature for vascular diseases. Circulation 2008; 118: 2826-2829.
3. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, Hailpern SM, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O'Donnell C, Roger V, Sorlie P, Steinberger J, Thom T, Wilson M, Hong Y; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 117: e25-146.
4. Belch JJ, Topol EJ, Agnelli G, Bertrand M, CaliffRM, Clement DL, Creager MA, Easton JD, Gavin JR 3rd, Greenland P, Hankey G, HanraThP, Hirsch AT, Meyer J, SmiThSC, Sullivan F, Weber MA; Prevention of Atherothrombotic Disease Network. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med 2003; 163: 884-892.
5. Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S, Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation 1985; 71: 510-515.
6. Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: the Framingham Study. J Am Geriatr Soc 1985; 33: 13-18.
7. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, Krook SH, Hunninghake DB, Comerota AJ, Walsh ME, McDermott MM, Hiatt WR. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286: 1317-1324.
8. Meijer WT, Hoes AW, Rutgers D, Bots ML, Hofman A, Grobbee DE. Peripheral arterial disease in the elderly: The Rotterdam Study. Arterioscler Thromb Vasc Biol 1998; 18: 185-192.
9. Fowkes FG, Housley E, Cawood EH, Macintyre CC, Ruckley CV, Prescott RJ. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 1991; 20: 384-392.
10. McDermott MM, Greenland P, Liu K, Guralnik JM, Celic L, Criqui MH, Chan C, Martin GJ, Schneider J, Pearce WH, Taylor LM, Clark E. The ankle brachial index is associated wiThleg function and physical activity: the Walking and Leg Circulation Study. Ann Intern Med 2002; 136: 873-883.
11. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM Jr, White CJ, White J, White RA, Antman EM, SmiThSC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2005 Practice Guidelines for the management of patients wiThperipheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; Trans-Atlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006; 113: e463-e654.
12. Rooke TW, Hirsch AT, Misra S, Sidawy AN, Beckman JA, Findeiss L, Golzarian J, Gornik HL, JaffMR, Moneta GL, Olin JW, Stanley JC, White CJ, White JV, Zierler RE; American College of Cardiology Foundation Task Force; American Heart Association Task Force. Management of patients wiThperipheral artery disease (compilation of 2005 and 2011 ACCF/AHA Guideline Recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 61: 1555-1570.
13. Perlstein TS, Creager MA. The ankle-brachial index as a biomarker of cardiovascular risk: it's not just about the legs. Circulation 2009; 120: 2033-2035.
14. Stehouwer CD, Clement D, Davidson C, Diehm C, Elte JW, Lambert M, Sereni D; EFIM Vascular Medicine Working Group Peripheral arterial disease: a growing problem for the internist. European Journal of Internal Medicine 2009; 20: 132-138.
15. Sabouret P, Cacoub P, Dallongeville J, Krempf M, Mas JL, Pinel JF, Priollet P, Steg G, Taminau D, Montalescot G. REACH: international prospective observational registry in patients at risk of atherothrombotic events: results for the French arm at baseline and one year. Arch Cardiovasc Dis 2008; 101: 81-88.
16. Steg PG, Bhatt DL, Wilson PW, D'Agostino R, Sr, Ohman EM, Rother J, Liau CS, Hirsch AT, Mas JL, Ikeda Y, Pencina MJ, Goto S. One-year cardiovascular event rates in outpatients wiThatherothrombosis. JAMA 2007; 297: 1197-1206.
17. Aboyans V, Criqui MH, Abraham P, Allison MA, Creager MA, Diehm C, Fowkes FG, Hiatt WR, Jönsson B, Lacroix P, Marin B, McDermott MM, Norgren L, Pande RL, Preux PM, Stoffers HE, Treat-Jacobson D; American Heart Association Council on Peripheral Vascular Disease; Council on Epidemiology and Prevention; Council on Clinical Cardiology; Council on Cardiovascular Nursing; Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. Circulation. 2012; 126: 2890-2909.
18. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG; TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007; 45: 5-67.
19. Criqui MH, Alberts MJ, Fowkes FG, Hirsch AT, O'Gara PT, Olin JW. Atherosclerotic Peripheral Vascular Disease Symposium II: screening for atherosclerotic vascular diseases: should nationwide programs be instituted? Circulation 2008; 118: 2830-2836.
20. Espinola-Klein C, Rupprecht HJ, Bickel C, Lackner K, Savvidis S, Messow CM, Munzel T, Blankenberg S; AtheroGene Investigators. Different calculations of ankle-brachial index and their impact on cardiovascular risk prediction. Circulation. 2008;118: 961-967.
21. Beckman JA, JaffMR, Creager MA. The United States Preventive Services Task Force recommendation statement on screening for peripheral arterial disease: more harm than benefit? Circulation 2006; 114: 861-866.
22. Newman AB, Siscovick DS, Manolio TA, Polak J, Fried LP, Borhani NO, Wolfson SK. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular HealThStudy. Cardiovascular Heart Study (CHS) Collaborative Research Group. Circulation 1993; 88: 837-845.
23. Newman AB, Shemanski L, Manolio TA, Cushman M, Mittelmark M, Polak JF, Powe NR, Siscovick D. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular HealThStudy. The Cardiovascular HealThStudy Group. Arterioscler Thromb Vasc Biol. 1999 Mar; 19 (3): 538-45.
24. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National HealThand Nutrition Examination Survey, 1999-2000. Circulation. 2004; 110: 738-43.
25. Hooi JD, Kester AD, Stoffers HE, Rinkens PE, Knottnerus JA, van Ree JW. Asymptomatic peripheral arterial occlusive disease predicted cardiovascular morbidity and mortality in a 7-year follow-up study. J Clin Epidemiol. 2004; 57: 294-300.
26. oobay AV and Anand SS. Sensitivity and specificity of the ankle-brachial index to predict future cardiovascular outcomes: a systematic review. Arterioscler Thromb Vasc Biol 2005; 25: 1463-1469
27. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, Goto S, Liau CS, Richard AJ, Röther J, Wilson PW; REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients wiThatherothrombosis. JAMA. 2006; 295: 180-189.
28. Diehm C, Allenberg JR, Pittrow D, Mahn M, Tepohl G, Haberl RL, Darius H, Burghaus I, Trampisch HJ; German Epidemiological Trial on Ankle Brachial Index Study Group. Mortality and vascular morbidity in older adults wiThasymptomatic versus symptomatic peripheral artery disease. Circulation 2009; 120: 2053-2061.
29. Criqui MH, McClelland RL, McDermott MM, Allison MA, Blumenthal RS, Aboyans V, Ix JH, Burke GL, Liu K, Shea S. The ankle-brachial index and incident cardiovascular events in the MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2010; 56: 1506-12.
30. Cimminiello C, Kownator S, Wautrecht JC, Carvounis CP, Kranendonk SE, Kindler B, Mangrella M, Borghi C; for the PANDORA Study Investigators. The PANDORA study: peripheral arterial disease in patients wiThnon-high cardiovascular risk. Intern Emerg Med 2011; 6: 509-519.
31. Violi F, Daví G, Hiatt W, Lip GY, Corazza GR, Perticone F, Proietti M, Pignatelli P, Vestri AR, Basili S; ARAPACIS Study Investigators. Prevalence of peripheral artery disease by abnormal ankle-brachial index in atrial fibrillation: implications for risk and therapy. J Am Coll Cardiol. 2013; 62: 2255-6.
32. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, Mc-Cann TJ, Browner D. Mortality over a period of 10 years in patients wiThperipheral arterial disease. N Engl J Med 1992; 326: 381-386.
33. Leng GC, Lee AJ, Fowkes FG, Whiteman M, Dunbar J, Housley E, Ruckley CV. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol 1996; 25: 1172-1181.
34. Ankle Brachial Index Collaboration, Fowkes FG, Murray GD, Butcher I, Heald CL, Lee RJ, Chambless LE, Folsom AR, Hirsch AT, Dramaix M, deBacker G, Wautrecht JC, Kornitzer M, Newman AB, Cushman M, Sutton-Tyrrell K, Fowkes FG, Lee AJ, Price JF, d'Agostino RB, Murabito JM, Norman PE, Jamrozik K, Curb JD, Masaki KH, Rodríguez BL, Dekker JM, Bouter LM, Heine RJ, Nijpels G, Stehouwer CD, Ferrucci L, McDermott MM, Stoffers HE, Hooi JD, Knottnerus JA, Ogren M, Hedblad B, Witteman JC, Breteler MM, Hunink MG, Hofman A, Criqui MH, Langer RD, Fronek A, Hiatt WR, Hamman R, Resnick HE, Guralnik J, McDermott MM. Ankle brachial index combined wiThFramingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA 2008; 300: 197-208.
35. Resnick HE, Lindsay RS, McDermott MM, Devereux RB, Jones KL, Fabsitz RR, Howard BV. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation 2004; 109: 733-739.
36. O'Hare AM, Katz R, Shlipak MG, Cushman M, Newman AB. Mortality and cardiovascular risk across the ankle-arm index spectrum: results from the Cardiovascular HealThStudy. Circulation 2006; 113: 388-393.
37. McDermott MM, Liu K, Criqui MH, RuThK, GoffD, Saad MF, Wu C, Homma S, Sharrett AR. Ankle brachial index and subclinical cardiac and carotid disease: the Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol 2005; 162: 33-41.
38. Dhangana R, Murphy TP, Coll JR, Ahn SH, Zafar AM, Qadeer FF, Hiatt WR. Prevalence of Abnormal Ankle-Brachial Index Among Individuals WiThLow or Intermediate Framingham Risk Scores. J Vasc Interv Radiol. 2011; 22: 1077-1082.
39. Hussein AA, Uno K, Wolski K, Kapadia S, Schoenhagen P, Tuzcu EM, Nissen SE, Nicholls SJ. Peripheral arterial disease and progression of coronary atherosclerosis. J Am Coll Cardiol 2011; 57: 1220-1225.
40. Leng GC, Fowkes FG, Lee AJ, Dunbar J, Housley E, Ruckley CV. Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study. BMJ 1996; 313: 1440-1444.
41. Violi F, Lip GY, Basili S. Peripheral artery disease and atrial fibrillation: a potentially dangerous combination. Intern Emerg Med. 2012; 7: 213-218.
42. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Kay GN, Le Huezey JY, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann LS. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/ AHA/ESC 2006 Guidelines for the management of patients wiThatrial fibrillation: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines developed in partnership wiThthe European Society of Cardiology and in collaboration wiThthe European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol. 2011; 57: e101-198.
43. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010; 137: 263-72.
44. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324: 71-86.
45. Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009; 373: 1849-60.
46. Davì G, Gresele P, Violi F, Basili S, Catalano M, Giammarresi C, Volpato R, Nenci GG, Ciabattoni G, Patrono C. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated wiThpersistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. Circulation 1997; 96: 69-75.
47. Kudoh T, Sakamoto T, Miyamoto S, Matsui K, Kojima S, Sugiyama S, Yoshimura M, Ozaki Y, Ogawa H. Relation between platelet microaggregates and ankle brachial index in patients wiThperipheral arterial disease. Thromb Res. 2006; 117: 263-9.
48. Blann AD, Tan KT, Tayebjee MH, Davagnanam I, Moss M, Lip GY. Soluble CD40L in peripheral artery disease. Relationship wiThdisease severity, platelet markers and the effects of angioplasty. Thromb Haemost. 2005; 93: 578324-83.
49. Violi F, Basili S, Berger JS, Hiatt WR. Antiplatelet therapy in peripheral artery disease. Handb Exp Pharmacol. 2012; 210: 547-563.
50. German Society of Angiology and Society for Vascular Medicine Guidelines http://www.leitlinien.de/mdb/downloads/dga/diagnostik-therapie-pavk-lang .pdf Accessed March 25, 2014.
51. European Stroke Organisation, Tendera M, Aboyans V, Bartelink ML, Baumgartner I, Clément D, Collet JP, Cremonesi A, De Carlo M, Erbel R, Fowkes FG, Heras M, Kownator S, Minar E, Ostergren J, Poldermans D, Riambau V, Roffi M, Röther J, Sievert H, van Sambeek M, Zeller T; ESC Committee for Practice Guidelines. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, re nal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2011; 32: 2851-2906.
52. Bell AD, Roussin A, Cartier R, Chan WS, Douketis JD, Gupta A, Kraw ME, Lindsay TF, Love MP, Pannu N, Rabasa-Lhoret R, Shuaib A, Teal P, Théroux P, Turpie AG, Welsh RC, Tanguay JF. The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society Guidelines Executive Summary. Can J Cardiol. 2011 Mar-Apr; 27 (2): 208-21.
53. Layden J, Michaels J, Bermingham S, Higgins B; Guideline Development Group. Diagnosis and management of lower limb peripheral arterial disease: summary of NICE guidance. BMJ. 2012 Aug 8; 345: e4947.
54. Alonso-Coello P, Bellmunt S, Mc-Gorrian C, Anand SS, Guzman R, Criqui MH, Akl EA, Olav Vandvik P, Lansberg MG, Guyatt GH, Spencer FA; American College of Chest Physicians. Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9Thed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141: e669-690.
55. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996; 348: 1329325-1339.
56. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, Lee R, Bancroft J, MacEwan S, Shepherd J, Macfarlane P, Morris A, Jung R, Kelly C, Connacher A, Peden N, Jamieson A, Matthews D, Leese G, McKnight J, O'Brien I, Semple C, Petrie J, Gordon D, Pringle S, MacWalter R; Prevention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients wiThdiabetes and asymptomatic peripheral arterial disease. BMJ. 2008; 337: a1840.
57. Cacoub PP, Bhatt DL, Steg PG, Topol EJ, Creager MA; CHARISMA Investigators. Patients wiThperipheral arterial disease in the CHARISMA trial. Eur Heart J. 2009; 30:192-201.
58. Fowkes FG, Price JF, Stewart MC, Butcher I, Leng GC, Pell AC, Sandercock PA, Fox KA, Lowe GD, Murray GD; Aspirin for Asymptomatic Atherosclerosis Trialists. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 2010; 303: 841-848.
59. Basili S, Raparelli V, Vestri A, Di Tanna GL, Violi F. Comparison of efficacy of antiplatelet treatments for patients wiThclaudication. A meta-analysis. Thromb Haemost 2010; 103: 766-773.
60. Berger JS, Krantz MJ, Kittelson JM, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients wiThperipheral artery disease: a meta-analysis of randomized trials. JAMA 2009; 301: 1909-1919.
61. Wong PF, Chong LY, Stansby G. Antiplatelet therapy to prevent cardiovascular events and mortality in patients wiThintermittent claudication. JAMA. 2013; 309: 926-927.